MiMedx announces strategic collaboration with Vaporox

MiMedx (MDXG) Group and Vaporox jointly announced a collaboration, whereby the companies will co-promote and co-market their wound care offerings. As part of the agreement, MIMEDX has made an investment in Vaporox and the Company has certain exclusivity rights related to potential acquisition discussions. “We are thrilled to continue delivering on our strategic goal of greater portfolio diversification through this collaboration with Vaporox,” commented Joseph Capper, MIMEDX Chief Executive Officer. “Together with our leading placental allografts, VHT will offer clinicians across numerous care settings another proven option to treat chronic, hard-to-heal wounds. We view this as a highly complementary addition that will help us grow in this important setting, where patients with difficult wounds often begin their recovery.”